Gamida Cell Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
148
- Latest Deal Type
-
Bankr. Admin/Reorg
- Latest Deal Amount
-
$30M
- Investors
-
1
Gamida Cell General Information
Description
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Contact Information
Website
www.gamida-cell.comCorporate Office
- 116 Huntington Avenue
- 7th Floor
- Boston, MA 02116
- United States
Corporate Office
- 116 Huntington Avenue
- 7th Floor
- Boston, MA 02116
- United States
Gamida Cell Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 19. Bankruptcy: Admin/Reorg | 13-May-2024 | $30M | Completed | Bankruptcy: Admin/Reorg | ||
| 18. Debt - General | 12-Dec-2022 | Completed | Generating Revenue/Not Profitable | |||
| 17. 2PO | 28-Jun-2019 | Completed | Generating Revenue | |||
| 16. IPO | 26-Oct-2018 | Completed | Generating Revenue | |||
| 15. Secondary Transaction - Private | 19-Jul-2018 | Completed | Clinical Trials - Phase 3 | |||
| 14. Grant | 20-Jul-2017 | Completed | Clinical Trials - Phase 3 | |||
| 13. Later Stage VC | 19-Jun-2017 | Completed | Clinical Trials - Phase 3 | |||
| 12. Grant | 23-May-2016 | Completed | Clinical Trials - Phase 3 | |||
| 11. Later Stage VC | 13-Oct-2015 | $5M | $88.8M | Completed | Clinical Trials - Phase 2 | |
| 10. Later Stage VC | 19-Aug-2014 | $35M | $83.8M | Completed | Clinical Trials - Phase 2 |
Gamida Cell Comparisons
Industry
Financing
Details
Gamida Cell Competitors (32)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Corvus Pharmaceuticals | Formerly VC-backed | Burlingame, CA | ||||
| JW Therapeutics | Formerly VC-backed | Shanghai, China | ||||
| Arvinas | Formerly VC-backed | New Haven, CT |
Gamida Cell Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Gamida Cell Patents
Gamida Cell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022328259-A1 | Anti-her2 car nk cells, methods of their production and uses thereof | Pending | 10-Aug-2021 | ||
| AU-2022325816-A1 | Engineered nk cells, methods of their production and uses thereof | Pending | 10-Aug-2021 | ||
| CA-3228570-A1 | Engineered nk cells, methods of their production and uses thereof | Pending | 10-Aug-2021 | ||
| EP-4384542-A1 | Anti-her2 car nk cells, methods of their production and uses thereof | Pending | 10-Aug-2021 | ||
| EP-4384603-A1 | Engineered nk cells, methods of their production and uses thereof | Pending | 10-Aug-2021 | C12N5/0646 |
Gamida Cell Executive Team (24)
| Name | Title | Board Seat |
|---|---|---|
| Josh Patterson | Chief Compliance Officer & General Counsel | |
| Penny Bushell | Chief Human Resources Officer | |
| Peter McMahon | Chief Human Resources Officer | |
| Tony Peled | Chief Scientific Officer, Vice President of Research & Development & Co-Founder | |
| Ronit Simantov MD | Chief Medical Officer & Chief Scientific Officer |
Gamida Cell Board Members (17)
| Name | Representing | Role | Since |
|---|---|---|---|
| Stephen Wills | Self | Board Member |
Gamida Cell Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Gamida Cell Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Highbridge Capital Management | Hedge Fund | Majority |
Gamida Cell FAQs
-
When was Gamida Cell founded?
Gamida Cell was founded in 1998.
-
Who is the founder of Gamida Cell?
Tony Peled is the founder of Gamida Cell.
-
Who is the CEO of Gamida Cell?
Joseph Wiley is the CEO of Gamida Cell.
-
Where is Gamida Cell headquartered?
Gamida Cell is headquartered in Boston, MA.
-
What is the size of Gamida Cell?
Gamida Cell has 148 total employees.
-
What industry is Gamida Cell in?
Gamida Cell’s primary industry is Biotechnology.
-
Is Gamida Cell a private or public company?
Gamida Cell is a Private company.
-
What is Gamida Cell’s current revenue?
The current revenue for Gamida Cell is .
-
How much funding has Gamida Cell raised over time?
Gamida Cell has raised $30M.
-
Who are Gamida Cell’s investors?
Highbridge Capital Management has invested in Gamida Cell.
-
Who are Gamida Cell’s competitors?
NexImmune, Kite Pharma, Corvus Pharmaceuticals, JW Therapeutics, and Arvinas are some of the 32 competitors of Gamida Cell.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
